The business model of Neuronetics Inc. focuses on providing innovative medical technology solutions for patients suffering from psychiatric disorders, particularly major depressive disorder (MDD). As a leading medical device company, Neuronetics specializes in developing and commercializing NeuroStar® Advanced Therapy, an FDA-cleared non-invasive transcranial magnetic stimulation (TMS) system. This breakthrough treatment option offers a safe and effective alternative to traditional antidepressant medications. Neuronetics offers a comprehensive approach, combining their advanced TMS technology with clinical support and patient education. By addressing the unmet needs of individuals with MDD, Neuronetics aims to improve the quality of life for patients and enhance mental health treatment outcomes.

Neuronetics Inc is primarily active in the healthcare industry.

The main competitors of Neuronetics Inc in the market include companies such as MagVenture, BrainsWay, and Fisher Wallace.

Neuronetics Inc is a reputable medical device company founded in 2003. Headquartered in Pennsylvania, the company focuses on developing innovative treatments for psychiatric disorders, specifically major depressive disorder (MDD). Neuronetics Inc is widely recognized for its groundbreaking invention, NeuroStar Advanced Therapy system, which utilizes transcranial magnetic stimulation (TMS) to alleviate depressive symptoms. With a commitment to providing non-invasive and effective solutions, Neuronetics Inc has gained significant recognition within the medical community. Over the years, the company has strived to improve patients' well-being and enhance mental health treatment options, solidifying its position as a leader in the field of neuromodulation therapies.

Neuronetics Inc has achieved significant milestones since its inception. The company introduced the NeuroStar Advanced Therapy, an FDA-cleared transcranial magnetic stimulation (TMS) system, which has revolutionized the treatment of depression. Neuronetics Inc expanded its reach by attaining various regulatory clearances globally, allowing patients worldwide to benefit from TMS therapy. The company also secured multiple strategic partnerships, further enhancing its market presence and advancing the field of neuromodulation. Neuronetics Inc's dedication to research and innovation has led to numerous clinical publications highlighting the effectiveness of NeuroStar TMS therapy. With its relentless pursuit of advancing psychiatric care, Neuronetics Inc continues to make significant strides in improving patient outcomes and quality of life.

Neuronetics Inc is primarily present in the United States.

Neuronetics Inc represents values of innovation, patient-centricity, and continuous improvement. With a corporate philosophy focused on developing advanced solutions for mental health disorders, Neuronetics Inc strives to improve the lives of individuals suffering from depression. The company's NeuroStar Advanced Therapy system, utilizing transcranial magnetic stimulation, is a testament to their commitment to innovation and providing effective treatment options. By placing patients at the center of their efforts, Neuronetics Inc aims to enhance mental health outcomes and restore hope for those in need.

Analysts currently set an average price target of 3.06 USD for the Neuronetics stock (median: 3.06 USD), implying +51.5 % versus the latest price. The consensus is based on 9 analyst ratings.

Neuronetics Analyst Price Targets 2026

9 analysts currently rate the Neuronetics stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Neuronetics to generate revenue of 165.72 M USD and earnings per share of -0.47 USD.

Neuronetics Analyst Price Targets 2026

Converted at the current exchange rate, the Neuronetics share trades at 1.77 EUR (2.02 USD).

The Neuronetics share (STIM) is listed on 3 stock exchanges, including: NASDAQ (STIM), Frankfurt (NRC.F), München (NRC.MU).

Neuronetics Inc. is a leading manufacturer of medical devices that help patients with mental disorders such as depression. The company is headquartered in Malvern, Pennsylvania, USA. Neuronetics Inc.'s business model is based on selling devices for Transcranial Magnetic Stimulation (TMS). TMS is a non-invasive method for treating severe depression in patients who have not responded to other treatment methods. The method uses high-intensity magnetic pulses to stimulate the brain, resulting in a reduction of symptoms. The company's core product is the NeuroStar Advanced Therapy System (ATS). The system consists of a TMS device and a specialized treatment chair. The chair can be individually adjusted to meet the patient's needs for optimal treatment. The NeuroStar ATS is the first TMS therapy in the USA to be approved by the Food and Drug Administration (FDA) for use in patients with depression. Neuronetics Inc. distributes its products through a broad sales structure. The company has its own sales representatives who handle the sales and marketing of the products in the USA and Europe. In addition, Neuronetics Inc. collaborates with distribution partners to distribute its products in countries where the company is not directly represented. The company also has a strong research component. Neuronetics Inc. has established a network of clinics and research institutions that participate in clinical studies on TMS therapy. The company also supports independent researchers working on the development of new applications of TMS therapy. Neuronetics Inc. works closely with health insurance companies and private insurers to ensure that its products can be used by as many patients as possible. The company maintains constant contact with healthcare decision-makers and organizes regular conferences and workshops to inform about the possibilities of TMS therapy. In summary, Neuronetics Inc. is an innovative company dedicated to the treatment of patients with severe depression. The company offers a high-quality and safe treatment system that has already been successfully used by many patients. With its broad sales structure and strong research component, Neuronetics Inc. is well positioned to continue to play a leading role in the market for TMS therapy.

The expected revenue of Neuronetics is 165.72 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Neuronetics is -30.94 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Neuronetics is currently -4.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Neuronetics stock.

The price-to-sales ratio (P/S) of Neuronetics is currently 0.80. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Neuronetics stock.

The Eulerpool Quality Score for Neuronetics is 3/10.

The ISIN of Neuronetics is US64131A1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Neuronetics is A2JPMY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Neuronetics is STIM. The ticker symbol is used to trade Neuronetics shares on the stock exchange.

Neuronetics paid dividends every year for the past 0 years.

Neuronetics is assigned to the 'Health' sector.

The dividends of Neuronetics are distributed in USD.